Fed. Circ. Strikes Down More Myriad Cancer Test Patents
The Federal Circuit ruled Wednesday that three Myriad Genetics Inc. breast cancer test patents are invalid for claiming patent-ineligible subject matter, another major setback for the company after the U.S. Supreme...To view the full article, register now.
Already a subscriber? Click here to view full article